[
    [
        {
            "time": "",
            "original_text": "【光大海外】策略系列（3）医药：大破大立：不经一番寒彻骨，怎得梅花扑鼻香——医药生物行业2019年度A+H投资策略",
            "features": {
                "keywords": [
                    "医药",
                    "大破大立",
                    "投资策略",
                    "医药生物行业",
                    "A+H"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "【光大海外】策略系列（3）医药：大破大立：不经一番寒彻骨，怎得梅花扑鼻香——医药生物行业2019年度A+H投资策略",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 8,
                "Source_Recency": 3
            }
        }
    ]
]